rethinkPeptides Search
Menu
Study breakdown

Optimizing Glucagon for Medical Use: Better Diabetes and Obesity Drug Candidates

evidence
The takeaway

Systematic optimization of the native glucagon sequence produced analogs with improved stability, selectivity, and pharmacokinetics for potential dual GLP-1/glucagon receptor agonist obesity and diabetes drugs.

Key finding

Systematic optimization of the native glucagon sequence produced analogs with improved stability, selectivity, and pharmacokinetics for potential dual

What the researchers found

Systematic optimization of the native glucagon sequence produced analogs with improved stability, selectivity, and pharmacokinetics for potential dual GLP-1/glucagon receptor agonist obesity and diabetes drugs.

Why it matters

Relevant for peptide research.

How the study worked

research study.

What this study cannot tell us

See abstract.

How to read the evidence

emerging evidence.

When this study was published

Published in 2010.

The bigger picture

Advances peptide research.

Questions still open

  • Further research needed.

Common questions

What was studied?
Optimizing Glucagon for Medical Use: Better Diabetes and Obesity Drug Candidates
What was found?
Systematic optimization of the native glucagon sequence produced analogs with improved stability, selectivity, and pharmacokinetics for potential dual GLP-1/glucagon receptor agonist obesity and diabetes drugs.

Read the original research

Optimization of the native glucagon sequence for medicinal purposes.

Journal of diabetes science and technology, 4(6), 1322-31

Citation

Chabenne, Joseph R; DiMarchi, Maria A; Gelfanov, Vasily M; DiMarchi, Richard D. (2010). Optimization of the native glucagon sequence for medicinal purposes.. Journal of diabetes science and technology, 4(6), 1322-31.